Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 162Myelodysplastic Syndromes 46Leukemia, Myelomonocytic, Chronic 26Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Leukemia, Biphenotypic, Acute 7Primary Myelofibrosis 6Neoplasms 6Lymphoma, T-Cell, Peripheral 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Anemia, Refractory, with Excess of Blasts 5Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 27Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11Drug Therapy 10anlotinib 9Radiotherapy 9Paclitaxel 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Azacitidine × 1 year × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡